Product Overview

Siphene 50 mg is a prescription medication that contains clomiphene citrate, a well‑studied selective estrogen receptor modulator (SERM). It is manufactured by Serum Institute India and supplied in sealed strips that each contain five tablets, with each tablet delivering a precise 50 mg dose of the active ingredient. The product is specifically indicated for the treatment of female infertility associated with ovulatory dysfunction, including polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, and other conditions that result in irregular or absent ovulation. Pack sizes of 30, 60, and 90 tablets are offered to accommodate different treatment durations, and the standard shipping window ranges from six to fifteen days depending on the destination and customs processing.

What is Siphene 50 mg (Clomiphene)

Clomiphene citrate has been used for more than five decades to stimulate ovulation in women who do not regularly release eggs. It functions by blocking estrogen receptors in the hypothalamus, which leads to an increase in the secretion of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. The resulting hormonal surge promotes the development of multiple ovarian follicles and ultimately triggers the release of a mature oocyte. Siphene is the generic name for this compound when marketed by Serum Institute India, and it is considered bioequivalent to other clomiphene products that have received approval from regulatory agencies such as the FDA and EMA. Pharmacokinetic studies show that the drug is rapidly absorbed after oral administration, reaches peak plasma concentrations within a few hours, and is metabolized primarily in the liver before being eliminated through biliary excretion.

Uses and Benefits

Siphene 50 mg is prescribed for women who have been diagnosed with infertility caused by ovulatory disorders. Clinical trial data indicate that approximately 70 % of properly selected patients achieve ovulation after one or more treatment cycles, and among those, roughly 30‑40 % achieve clinical pregnancy within six cycles of therapy. Because the medication is administered orally, it offers a non‑invasive alternative to injectable gonadotropins, which can be costly and require frequent monitoring. When used according to evidence‑based protocols, Siphene can improve ovulatory frequency, increase the likelihood of conception, and support timely pregnancy without the need for surgical interventions. In addition, the drug is generally well‑tolerated, and its side‑effect profile is manageable with appropriate medical supervision.

How It Works

The mechanism of action of clomiphene involves selective antagonism of estrogen receptors in the central nervous system. By blocking these receptors, the drug reduces the negative feedback effect of estrogen on the hypothalamic‑pituitary axis, resulting in an increase in gonadotropin‑releasing hormone (GnRH) pulses. This prompts the anterior pituitary to secrete higher amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). Elevated FSH stimulates the growth of multiple ovarian follicles, while the subsequent LH surge triggers the final maturation and release of the oocyte. Because multiple follicles may develop, clinicians typically monitor response with transvaginal ultrasound to minimize the risk of high‑order multiple pregnancies. Detailed pharmacodynamic data are available from the NIH and from peer‑reviewed journals.

Dosage Guidelines

Standard initiation of therapy consists of a single 50 mg tablet taken daily for five consecutive days, usually starting on the fifth day of the menstrual cycle. If ovulation does not occur, a physician may consider increasing the dose to 100 mg per day for subsequent cycles, but dosages above 150 mg are generally discouraged due to diminishing efficacy and an increased likelihood of adverse effects. Patients should be instructed to swallow the tablet whole with water and to avoid crushing or chewing it. Prior to starting treatment, a baseline evaluation that includes hormonal profiling, pelvic ultrasound, and assessment of ovarian reserve is recommended. Following the five‑day course, a follow‑up ultrasound is typically performed to assess follicular development and to determine whether ovulation has taken place. If ovulation is confirmed, timing of intercourse or intrauterine insemination can be coordinated to maximize conception chances.

Side Effects

Most patients experience mild and transient side effects, which may include hot flashes, abdominal discomfort, breast tenderness, and slight nausea. Less common adverse reactions include headache, visual disturbances, and the development of small, benign ovarian cysts that usually resolve without intervention. Rare but serious complications can involve ovarian hyperstimulation syndrome (OHSS), thromboembolic events, and allergic reactions such as skin rash or facial swelling. Patients should discontinue the medication and seek immediate medical attention if they experience severe abdominal pain, shortness of breath, or any signs of an allergic response. For a complete list of reported side effects, consult Drugs.com and discuss any concerns with a qualified healthcare professional.

Warnings and Precautions

Siphene is contraindicated in women who are pregnant, have known liver disease, or suffer from uncontrolled thyroid or adrenal disorders. The drug should not be used by individuals with a documented hypersensitivity to clomiphene or any inactive ingredients in the formulation. Caution is advised in patients with a history of depression, as hormonal fluctuations can potentially exacerbate mood symptoms. Concomitant use of other fertility medications, especially gonadotropins, should be reviewed carefully to avoid excessive ovarian stimulation. Women who are breastfeeding should avoid Siphene, as the drug may be excreted in breast milk. The official FDA prescribing information provides comprehensive guidance on contraindications, warnings, and drug interactions.

FAQs

Q1: How long does it take to see ovulation after starting Siphene?
A: Ovulation typically occurs 6‑10 days after the last tablet, but individual response can vary; ultrasound monitoring is recommended to confirm follicular rupture and timing of intercourse.

Q2: Can Siphene increase the chance of multiple pregnancies?
A: Yes, the medication can stimulate the development of multiple follicles, which raises the risk of twins or higher‑order multiples; careful ultrasound monitoring and dose adjustment help mitigate this risk.

Q3: Is a prescription required to purchase Siphene 50 mg?
A: In most countries, Siphene is a prescription‑only medication; a licensed physician must evaluate a patient’s medical history and fertility status before prescribing it.

Q4: Where can I find more scientific information about clomiphene?
A: Comprehensive pharmacologic data are available from the NIH Bookshelf, the FDA, and MedlinePlus. Additional peer‑reviewed studies can be accessed via PubMed.

Q5: What should I do if I miss a dose?
A: If a dose is missed, the tablet should be taken as soon as the patient remembers, provided that it is still within the five‑day treatment window; if it is close to the time of the next scheduled dose, the missed tablet should be skipped and the regular dosing schedule resumed.

Related Products

• CB-Lin (Cabergoline)
• Meprate 10 mg (Medroxyprogesterone)
• Sicriptin 2.5 mg Tablets (Bromocriptine)
• Sicriptin 1.25 mg Tablets (Bromocriptine)
• Sicriptin (Bromocriptine)
• Bromocriptine 1.25 mg (Generic)
• Bromocriptine 2.5 mg (Generic)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 50 mg (Generic)